Peptide Initiative

Peptides · Peptide comparison

Lixisenatide vs Retatrutide

Short-acting prandial GLP-1 receptor agonist for postprandial glucose control

The world's first triple-action weight loss peptide that simultaneously activates three hormone receptors—GIP, GLP-1, and glucagon—delivering unprecedented weight loss results of up to 24% body weight in clinical trials [1][2].

  • Weight Management
  • Weight Management

At a glance

Quick comparison

Dose rangeLixisenatide20–20 mcgRetatrutide4–8 mg
FrequencyLixisenatideOnce dailyRetatrutideOnce weekly
AdministrationLixisenatidesubcutaneous injectionRetatrutideSubcutaneous injection
Cycle lengthLixisenatideOngoing/indefiniteRetatrutide12+ weeks
Onset speedLixisenatideModerate (1-2 weeks)RetatrutideModerate (1-2 weeks)
Evidence levelLixisenatideStrong human trials (Phase 3 or FDA approved)RetatrutideModerate human trials (Phase 1-2)

Efficacy

Benefit ratings

Blood Sugar Control

Lixisenatide9%
RetatrutideNo recorded rating

Cardiovascular Safety

Lixisenatide7%
RetatrutideNo recorded rating

Weight Management

Lixisenatide6%
RetatrutideNo recorded rating

Weight Loss Power

LixisenatideNo recorded rating
Retatrutide98%

Metabolic Health

LixisenatideNo recorded rating
Retatrutide95%

Appetite Control

LixisenatideNo recorded rating
Retatrutide94%

Technical data

Compound specifications

Lixisenatide

Molecular formula
C215H347N61O65S
Molecular weight
4,858 Da
Half-life
2.8-3 hours
Bioavailability
55% subcutaneous bioavailability
CAS number
320367-13-3

Retatrutide

Molecular formula
C221H342N46O68
Molecular weight
4731 g/mol
Half-life
~6 days (allows once-weekly dosing)
Bioavailability
High via subcutaneous injection
CAS number
2381089-83-2

Protocols

Dosing compared

Lixisenatide

Subcutaneous

  • Weeks 1-210 mcgOnce daily · Days 1-14FDA-label (Adlyxin) starting dose given once daily for 14 days using the green starter pen; injected in abdomen, thigh, or upper arm within one hour before the first meal of the day [6].
  • Day 1520 mcgOnce daily · From day 15 onwardFDA-label maintenance dose, started on day 15 using the burgundy pen for ongoing type 2 diabetes glycemic control [6].

Retatrutide

Subcutaneous

  • Weeks 1-42 mgOnce weekly · Weeks 1-4 (then escalate 2 mg every 4 weeks)Phase 2 obesity trial initiated higher-dose arms at 2 mg weekly with stepwise 2 mg increases every 4 weeks to limit GI effects [1].
  • Maintenance after titration4-8 mgOnce weekly · Maintenance after titrationMid-range maintenance doses; 8 mg produced ~22% mean weight loss at 48 weeks in the phase 2 trial [1][3].
  • Maintenance (highest studied)12 mgOnce weekly · Maintenance (highest studied)Highest studied dose; produced ~24% mean weight reduction at 48 weeks [1]. Still investigational (not FDA-approved).

Applications

Best suited for

Lixisenatide

Managing postprandial hyperglycemia in type 2 diabetes
Lixisenatide is particularly well-suited for individuals focused on managing postprandial hyperglycemia in type 2 diabetes. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Improving glycemic control as add-on to oral antidiabetics
Lixisenatide is particularly well-suited for individuals focused on improving glycemic control as add-on to oral antidiabetics. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Supporting weight management in T2DM patients
Lixisenatide is particularly well-suited for individuals focused on supporting weight management in t2dm patients. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Combination therapy with basal insulin glargine
Lixisenatide is particularly well-suited for individuals focused on combination therapy with basal insulin glargine. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Retatrutide

Significant Obesity Management
If you need to lose a substantial amount of weight, retatrutide is showing unprecedented results. Phase 2 trials demonstrated average weight loss of 24% at the highest dose—that's nearly 60 pounds for someone weighing 250 lbs [1]. No other medication has matched this [1].
Type 2 Diabetes with Obesity
Retatrutide tackles both problems at once. It dramatically improves blood sugar control (HbA1c reductions of up to 2%) while delivering major weight loss [6]. The dual benefit makes it especially valuable for diabetics struggling with weight.
Metabolic Syndrome Warriors
If you're dealing with the cluster of issues that includes high blood sugar, excess belly fat, abnormal cholesterol, and high blood pressure, retatrutide's triple mechanism attacks multiple aspects of metabolic dysfunction simultaneously [5].
Fatty Liver Disease (MASLD)
Early research shows retatrutide may significantly reduce liver fat [7]. For people with non-alcoholic fatty liver disease, this peptide offers hope through weight loss plus direct metabolic improvements that benefit liver health.

Safety profile

Side effects

Lixisenatide

Common

  • Nausea
  • Vomiting
  • Diarrhea
  • Headache

Uncommon

  • Injection Site Reactions

Serious

  • Acute Pancreatitis

Retatrutide

Common

  • Nausea
  • Diarrhea
  • Constipation
  • Decreased appetite

Uncommon

  • Increased heart rate
  • Injection site reactions

Serious

  • Pancreatitis
  • Gallbladder problems

Research status

Safety & evidence

Lixisenatide

Evidence level
Strong human trials (Phase 3 or FDA approved)
FDA status
FDA approved for this use
Safety overview
Lixisenatide (ADLYXIN in the US, Lyxumia in the EU) is an FDA-approved GLP-1 receptor agonist for type 2 diabetes; its safety record comes from the GetGoal phase 3 trials and the ELIXA cardiovascular outcomes trial. [1][6] In the pooled placebo-controlled trials, gastrointestinal reactions affected 39.7% of patients against 18.4% on placebo, mostly in the first 3 weeks; nausea affected 25% and vomiting 10%. [6] Labelled warnings cover anaphylaxis and serious hypersensitivity, pancreatitis (21 cases on lixisenatide against 14 on comparators), hypoglycemia when combined with a sulfonylurea or basal insulin, acute kidney injury after severe GI fluid loss, antibody formation and gallbladder disease. [6] Unlike the long-acting GLP-1 agonists, its label carries no boxed thyroid C-cell tumor warning. [6]

Contraindications

  • Known hypersensitivity to lixisenatide or excipients [6]

Retatrutide

Evidence level
Moderate human trials (Phase 1-2)
FDA status
Research compound
Safety overview
Retatrutide has shown a generally favorable safety profile in Phase 1 and Phase 2 clinical trials involving over 600 participants [1][6]. Most side effects are gastrointestinal and tend to improve over time [3]. The medication appears well-tolerated when doses are increased gradually. No major safety signals have emerged, but larger Phase 3 trials are still ongoing [3].

Contraindications

  • Personal or family history of medullary thyroid carcinoma (MTC)
  • Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
  • Pregnancy or planning to become pregnant
  • History of severe pancreatitis
  • Known allergy to GLP-1 receptor agonists

Decision guide

Which is right for you?

Lixisenatide

Choose Lixisenatide if…

  • Managing postprandial hyperglycemia in type 2 diabetes
  • Improving glycemic control as add-on to oral antidiabetics
  • Supporting weight management in T2DM patients
  • Combination therapy with basal insulin glargine

Retatrutide

Choose Retatrutide if…

  • Significant weight loss
  • Type 2 diabetes management
  • Metabolic health improvement
  • Body composition optimization